**Errata for ERG report for STA 13/60 of empagliflozin for T2DM of 11 Nov 2014**

Page 64

The text

*Canagliflozin 300 mg when compared to empagliflozin 25 mg has a cost effectiveness estimate of £68,571 per QALY if there is no impact upon quality of life from weight changes. A BMI coefficient of -0.0038 reduces this to £7,869 per QALY, while a BMI coefficient of -0.0061 reduces it further to £5,139 per QALY, due to the greater weight loss associated with canagliflozin 300 mg.*

should read

*Canagliflozin 300 mg when compared to empagliflozin 25 mg has a cost effectiveness estimate of £8,241 per QALY if there is no impact upon quality of life from weight changes. A BMI coefficient of -0.0038 reduces this to £4,596 per QALY, while a BMI coefficient of -0.0061 reduces it further to £3,632 per QALY, due to the greater weight loss associated with canagliflozin 300 mg.*

Page 74

The text

*There is quite considerable variability within the modelled ICERs. The results of the NMA are appropriate as estimates for use in the cost effectiveness modelling, though it remains unclear to the ERG how the estimates for UTIs and GTIs have been derived.*

should read

*There is quite considerable variability within the modelled ICERs. The results of the NMA are appropriate as estimates for use in the cost effectiveness modelling, though it remains unclear to the ERG how the estimates for non-severe hypos and GTIs have been derived.*

We also append two corrected graphs of the NMA results.

The previously submitted weight gain graph had 24 week rather than 52 week data entered in error, now corrected.

For HbA1c, the comparison in triple therapy of empagliflozin 25 mg versus canagliflozin 300 mg had an error, now corrected.

**Mean difference in Body Weight change at 52 weeks**

| Therapy | empag | comparator | MD | LCI | UCI |
|---|---|---|---|---|---|
| Dual | empag 25 | placebo | -2.33 | -2.83 | -1.83 |
| Dual | empag 25 | Sulphonylurea | -4.80 | -5.10 | -4.50 |
| Dual | empag 25 | Empagliflozin 10mg | -0.58 | -1.10 | -0.06 |
| Dual | empag 25 | Dapagliflozin 10 mg | -0.12 | -0.65 | 0.41 |
| Dual | empag 25 | Canagliflozin 100 mg | -0.35 | -0.90 | 0.21 |
| Dual | empag 25 | Canagliflozin 300 mg | 0.00 | -0.55 | 0.56 |
| Dual | empag 25 | Sitagliptin 100 mg | -2.40 | -2.99 | -1.80 |
| *Dual* | *empag 10* | *placebo* | *-1.75* | *-2.27* | *-1.22* |
| *Dual* | *empag 10* | *Sulphonylurea* | *-4.22* | *-4.80* | *-3.63* |
| *Dual* | *empag 10* | *Empagliflozin 25mg* | *0.58* | *0.06* | *1.10* |
| *Dual* | *empag 10* | *Dapagliflozin 10 mg* | *0.47* | *-0.24* | *1.17* |
| *Dual* | *empag 10* | *Canagliflozin 100 mg* | *0.24* | *-0.51* | *0.99* |
| *Dual* | *empag 10* | *Canagliflozin 300 mg* | *0.59* | *-0.17* | *1.34* |
| *Dual* | *empag 10* | *Sitagliptin 100 mg* | *-1.81* | *-2.60* | *-1.03* |
| | | | | | |
| Triple | empag 25 | placebo | -2.05 | -2.56 | -1.55 |
| Triple | empag 25 | Empagliflozin 10mg | -0.05 | -0.59 | 0.49 |
| Triple | empag 25 | Canagliflozin 100mg | -0.77 | -1.75 | 0.19 |
| Triple | empag 25 | Canagliflozin 300mg | 0.22 | -0.74 | 1.20 |
| Triple | empag 25 | Sitagliptin 100mg | -2.42 | -3.45 | -1.38 |
| *Triple* | *empag 10* | *placebo* | *-2.00* | *-2.49* | *-1.51* |
| *Triple* | *empag 10* | *Empagliflozin 25mg* | *0.05* | *-0.49* | *0.59* |
| *Triple* | *empag 10* | *Canagliflozin 100mg* | *-0.72* | *-1.68* | *0.23* |
| *Triple* | *empag 10* | *Canagliflozin 300mg* | *0.28* | *-0.68* | *1.24* |
| *Triple* | *empag 10* | *Sitagliptin 100mg* | *-2.37* | *-3.40* | *-1.35* |
| | | | | | |
| insulin + on | empag 25 | placebo | -1.81 | -2.26 | -1.36 |
| insulin + on | empag 25 | Empagliflozin 10mg | -0.40 | -0.86 | 0.06 |
| insulin + on | empag 25 | Dapagliflozin2.5mg | -0.46 | -1.17 | 0.25 |
| insulin + on | empag 25 | Dapagliflozin 5mg | -0.38 | -1.08 | 0.33 |
| insulin + on | empag 25 | Dapagliflozin 10mg | 0.23 | -0.48 | 0.93 |
| *insulin + on* | *empag 10* | *placebo* | *-1.41* | *-1.82* | *-1.00* |
| *insulin + on* | *empag 10* | *Empagliflozin 25mg* | *0.40* | *-0.06* | *0.86* |
| *insulin + on* | *empag 10* | *Dapagliflozin2.5mg* | *-0.06* | *-0.74* | *0.62* |
| *insulin + on* | *empag 10* | *Dapagliflozin 5mg* | *0.02* | *-0.65* | *0.70* |
| *insulin + on* | *empag 10* | *Dapagliflozin 10mg* | *0.63* | *-0.05* | *1.31* |



**Mean difference in percentage change in HbA1c at 52 weeks**

| Therapy | empag | comparator | MD | LCI | UCI |
|---|---|---|---|---|---|
| Dual | empag 25 | placebo | -0.62 | -0.73 | -0.5 |
| Dual | empag 25 | Sulphonylurea | -0.1 | -0.17 | -0.02 |
| Dual | empag 25 | Empagliflozin 10mg | -0.03 | -0.16 | 0.1 |
| Dual | empag 25 | Dapagliflozin 10 mg | -0.15 | -0.26 | -0.03 |
| Dual | empag 25 | Canagliflozin 100 mg | -0.09 | -0.21 | 0.03 |
| Dual | empag 25 | Canagliflozin 300 mg | 0.03 | -0.08 | 0.15 |
| Dual | empag 25 | Sitagliptin 100 mg | -0.1 | -0.22 | 0.02 |
| *Dual* | *empag 10* | *placebo* | *-0.58* | *-0.72* | *-0.45* |
| *Dual* | *empag 10* | *Sulphonylurea* | *-0.06* | *-0.21* | *0.08* |
| *Dual* | *empag 10* | *Empagliflozin 25mg* | *0.03* | *0.16* | *-0.1* |
| *Dual* | *empag 10* | *Dapagliflozin 10 mg* | *-0.11* | *-0.27* | *0.04* |
| *Dual* | *empag 10* | *Canagliflozin 100 mg* | *-0.06* | *-0.23* | *0.11* |
| *Dual* | *empag 10* | *Canagliflozin 300 mg* | *0.07* | *-0.1* | *0.24* |
| *Dual* | *empag 10* | *Sitagliptin 100 mg* | *-0.07* | *-0.24* | *0.1* |
| Triple | empag 25 | placebo | -0.69 | -0.86 | -0.52 |
| Triple | empag 25 | Empagliflozin 10mg | 0.02 | 0.19 | -0.15 |
| Triple | empag 25 | Canagliflozin 100mg | 0.06 | 0.33 | -0.21 |
| Triple | empag 25 | Canagliflozin 300mg | 0.28 | 0.55 | 0.01 |
| Triple | empag 25 | Sitagliptin 100mg | -0.09 | 0.21 | -0.39 |
| *Triple* | *empag 10* | *placebo* | *-0.71* | *-0.88* | *-0.54* |
| *Triple* | *empag 10* | *Empagliflozin 25mg* | *-0.02* | *-0.19* | *0.15* |
| *Triple* | *empag 10* | *Canagliflozin 100mg* | *0.04* | *-0.23* | *0.31* |
| *Triple* | *empag 10* | *Canagliflozin 300mg* | *0.26* | *-0.01* | *0.53* |
| *Triple* | *empag 10* | *Sitagliptin 100mg* | *-0.11* | *-0.41* | *0.19* |
| insulin + on | empag 25 | placebo | -0.64 | -0.8 | -0.49 |
| insulin + on | empag 25 | Empagliflozin 10mg | -0.16 | -0.32 | 0 |
| insulin + on | empag 25 | Dapagliflozin2.5mg | -0.24 | -0.46 | -0.02 |
| insulin + on | empag 25 | Dapagliflozin 5mg | -0.14 | -0.36 | 0.07 |
| insulin + on | empag 25 | Dapagliflozin 10mg | -0.07 | -0.29 | 0.14 |
| *insulin + on* | *empag 10* | *placebo* | *-0.48* | *-0.64* | *-0.33* |
| *insulin + on* | *empag 10* | *Empagliflozin 25mg* | *0.16* | *0* | *0.32* |
| *insulin + on* | *empag 10* | *Dapagliflozin2.5mg* | *-0.08* | *-0.3* | *0.14* |
| *insulin + on* | *empag 10* | *Dapagliflozin 5mg* | *0.01* | *-0.2* | *0.23* |
| *insulin + on* | *empag 10* | *Dapagliflozin 10mg* | *0.08* | *-0.13* | *0.3* |